Abstract B50: Effects of automated tobacco assessment and cessation on survival for thoracic cancer patients
Authors: Amato Katharine Dobson , Reid Mary , Reed Robert , Hysert Patricia , Hysert Robert , Segal Stephanie , Giovino Gary , Travers Maansi , Ochs-Balcom Heather , Zevon Michael , Cummings Kenneth Michael , Nwogu Chukwumere , Marshall James , Mahoney Martin , Hyland Andrew , Warren Graham 
Published: May 2019

Abstract
Purpose: Most tobacco cessation studies in cancer patients rely upon retrospective reviews in a small subsample of cancer patients presenting for treatment. The purpose of this study is to describe the tobacco use and cessation patterns for all patients (100% sampling) presenting to a thoracic oncology clinic at a NCI Designated Comprehensive Cancer Center using a standardized assessment and automatic tobacco cessation referral program.
Methods: Patients presenting to the thoracic oncology clinic at Roswell Park Cancer Institute (RPCI) were screened with a standardized tobacco assessment and all patients who used tobacco within the past 30 days were automatically referred to a dedicated tobacco cessation program. Demographic and health information were obtained from the electronic medical record, as well as the RPCI tumor registry, for all thoracic patients referred to the cessation program between October 2010 and October 2012. Tobacco information was collected by the cessation specialist. Descriptive and multivariate analyses were used to identify significant associations between demographics and disease characteristics with participation rates and self-reported quit rates.
Results: Among the 978 patients referred to the cessation program, 531 (54.2%) had information in the tumor registry. 476 (89.6%) patients had a form of lung cancer and 55 (5.6%) had another thoracic cancer, such as esophageal, bronchial, thymus, mediastinum or pleura cancer. 226 out of the 531 (42.6%) patients with tumor registry information were deceased, of whom the majority died from the primary thoracic cancer or complication from that cancer (N=151/226; 66.8%). Among those who were deceased, those who self-reported former tobacco use status (not currently using) at the first visit had a significantly longer survival time (n=53; mean=20.40 months, SD=30.91) compared to current users at first visit (n=157; mean=13.75 months, SD=15.41; p=0.042). Change in quit status from diagnosis to the first contact was not statistically associated with survival outcomes after controlling for age, packyears, sex and clinical stage of disease. Compared to being a current tobacco user at diagnosis and first contact, a significant difference in survival was not observed among those who quit between diagnosis and the first contact by the cessation service (HR=1.16, 95%CI: 0.63-2.13), those who relapsed between diagnosis and the first contact (HR=0.80, 95% CI: 0.36-1.79), and those who self-reported being quit at diagnosis and the first contact (HR=0.61, 95% CI: 0.28-1.34). However, age (HR=1.03; 95% CI: 1.01-1.05); being male compared to female (HR=1.64; 95% CI: 1.07-2.51) and clinical stage of disease (clinical stage compared to stage 1: HRstage2=2.20; 95% CI: 0.84-5.78; HRstage3=3.48; 95% CI: 1.67-7.24; HRstage4=8.49; 95% CI: 4.35-16.58) were significantly associated with survival. Although the association of quitting after diagnosis and survival was not statistically significant, the number of those who quit was small, limiting statistical power.
Conclusions: Patients who participated in an automated institutional cessation program and who quit smoking may have a reduced risk of death.
Citation Format: Katharine Dobson Amato, Mary Reid, Robert Reed, Patricia Hysert, Robert Hysert, Stephanie Segal, Gary Giovino, Maansi Travers, Heather Ochs-Balcom, Michael Zevon, Kenneth Michael Cummings, Chukwumere Nwogu, James Marshall, Martin Mahoney, Andrew Hyland, Graham Warren. Effects of automated tobacco assessment and cessation on survival for thoracic cancer patients. [abstract]. In: Proceedings of the Twelfth Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2013 Oct 27-30; National Harbor, MD. Philadelphia (PA): AACR; Can Prev Res 2013;6(11 Suppl): Abstract nr B50.